BRIDGE-SIC Efficacy Trial
Part of paid clinical trials in Boston, Massachusetts.
- Sponsor
- Dana-Farber Cancer Institute
- Study ID
- NCT07735442
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Cancer
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- LLM-generated SIC summary email to clinical teams — BEHAVIORALAn email containing a summary of prior serious illness conversations, generated by a large language model, is sent to the patient's clinical teams at admission, prompting review and discussion of care preferences.
Study Details
This is a pragmatic, prospective, randomized clinical trial to test the effectiveness of large language model (LLM)-generated serious illness conversation (SIC) summaries delivered to patients' inpatient and outpatient clinicians at the time of hospital admission on the primary outcome of days in the hospital in the next 90 days.
Key Dates
- First listed
- Jul 30, 2026
- Start date
- Jul 31, 2026
- Status verified
- Jul 2026
- Primary completion
- Jun 30, 2027
- Completion
- Jun 30, 2028
Study Design
- Enrollment
- 600 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- SINGLE_GROUP
- Primary purpose
- OTHER
Arms
- Other: Arm 1: Intervention ArmPatients receive an email sent to their inpatient and outpatient clinical teams containing an LLM-generated summary of prior SIC documentation, prompting clinicians to review and discuss care preferences with the patient and align care with patient goals.
- No Intervention: Arm 2: Control ArmPatients receive standard of care; SICs may be initiated by patients or clinicians as usual.
Primary Outcome Measure
Number of Days in the Hospital [ Time Frame: 90 days after randomization ]
Central Contacts
- Alexi A Wright, MD, MPH6176322334
- Charlotta J Lindvall, MD, PhD6175823491
Locations (2)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Brigham and Women's Hospital | Boston | Massachusetts | 02214 | Alexi A Wright, MD, MPH (PRINCIPAL_INVESTIGATOR) Charlotta J Lindvall, MD PhD (PRINCIPAL_INVESTIGATOR) |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | Alexi A Wright, MD, MPH (PRINCIPAL_INVESTIGATOR) Charlotta J Lindvall, MD PhD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Boston, MA
Related Studies
- Evaluation of Non-Invasive Assays for the Detection of Urothelial CancerRecruiting · Lahey Clinic · Burlington, Massachusetts
- Childhood Cancer Survivor StudyRecruiting · St. Jude Children's Research Hospital · Birmingham, Alabama
- Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6PHASE2 · Recruiting · Dana-Farber Cancer Institute · Boston, Massachusetts
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryRecruiting · Massive Bio, Inc. · Birmingham, Alabama